FDA approves roflumilast foam 0.3% for scalp, body psoriasis ...

Read the full case presentation of a 21-month-old with a history of "skin tags" involving her gluteal cleft,noted at birth. Can you diagnose this patient? Take our poll and find out! Then check back ...

NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes.

The once-daily, steroid-free topical is now approved to treat plaque psoriasis of the scalp and body in patients aged 12 years and older.

For most teenagers, a psychosocial history is at least as important as the physical exam. This essential psychosocial history can be obtained using the HEEADSSS method of interviewing adolescents. The ...

In 2021, the American Academy of Pediatrics, American Academy of Child and Adolescent Psychiatry, and the Children’s Hospital Association jointly declared a national emergency in child and adolescent ...

Evidence suggests some pharmaceutical excipients in medications may have adverse effects on pediatric patients. Here’s what you should know. Ultimately, there is a paucity of safety data for several ...

Primary care clinicians play an essential role as first responders to children’s emotional and behavioral problems. Sixteen years ago, 15 of my colleagues and I—with the support of the new nonprofit ...

Part of the risk of developing kidney involvement begins when type 1 diabetes mellitus (T1DM) sets in and establishes itself in the patient, with up to 65% of children experiencing acute kidney injury ...

Based on current research, over 22 million adults have been targets of parental alienation in the United States. An estimated 10 million adults have experienced what they perceive to be severe ...

Caregivers and parents should feel empowered to protect their children with sun-safe practices that include sunscreen, sun-protective clothing, and sun-safe activities. According to the American ...

The approval follows a unanimous vote of support from the FDA Antimicrobial Drugs Advisory Committee of nirsevimab-alip’s favorable benefit-risk profile for the prevention of Respiratory Syncytial ...